Skip to content

Non-invasive Brain Stimulation to Improve Unsteady Gait in Older Adults (StimGait)

Modulating Brain Networks to Reduce Gait Variability in Older Adults at Risk of Falling

Status
Completed
Phases
Unknown
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT06008431
Enrollment
27
Registered
2023-08-23
Start date
2024-06-03
Completion date
2025-11-20
Last updated
2026-01-21

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Fall, Gait, Unsteady, Mobility Limitation

Keywords

transcranial direct current stimulation (tDCS), transcranial electrical stimulation (tES), Non-invasive brain stimulation (NIBS), Falls, Gait Variability, Sustained Attention, Dorsal Attention Network, Default Network

Brief summary

Walking is a complex and continuous task that entails repetitive motions of the body. Relatively high gait variability sensitively predicts falls and cognitive decline in older adults. Previous work has identified an unique brain network relationship linked to gait variability and its relevant cognitive function (i.e., sustained attention). This project aims to develop a non-invasive brain stimulation montage designed to modulate the shared brain networks dynamics and to demonstrate its effects on resting state functional connectivity, gait and cognitive performance in older adults at risk for falls.

Detailed description

This is a randomized controlled trial to examine the efficacy of a non-invasive brain stimulation intervention of tDCS to improve unsteady gait in older adults. The investigators will enroll 30 older adults with elevated gait variability. Participants will be randomized into one of two arms: a) 10 sessions of tDCS and b) 5 sessions of sham stimulation followed by 5 sessions of tDCS. Participants will engage in a set of pre-intervention assessments, the brain stimulation intervention - consisting of 10, once-daily, 20-min stimulation sessions over a 2-week period, and a set of post-intervention assessments. This project is expected to demonstrate that tDCS can be used to reduce gait variability in older adults.

Interventions

DEVICETranscranial direct current stimulation (tDCS) (active)

The tDCS montage is developed to modulate the functional connectivity between the dorsal attention network and the default network.

DEVICETranscranial direct current stimulation (tDCS) (Sham)

The tDCS "Acti-" Sham montage is developed to recreate the cutaneous sensations associated with tDCS, yet essentially a null electrical field over the networks of interest.

Sponsors

Hebrew SeniorLife
Lead SponsorOTHER
National Institute on Aging (NIA)
CollaboratorNIH

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
TRIPLE (Subject, Investigator, Outcomes Assessor)

Eligibility

Sex/Gender
ALL
Age
65 Years to No maximum
Healthy volunteers
Yes

Inclusion criteria

* Aged 65 and above. * Ability to speak and read English. * Ability to walk independently and continuously for at least 1 minute. * Elevated gait variability as defined by a coefficient of variation (CoV) about average stride time larger and equal to 0.025 during straight-line walking at preferred speed.

Exclusion criteria

* More than mild cognitive impairment defined by a Montreal Cognitive Assessment (MoCA) score less than 18. * Parkinson's disease, multiple sclerosis, stroke, active brain tumor, or other neurological disorders. * Self-reported pain or lower extremity deformity that significantly disrupts walking. * Contraindications to MRI or tDCS. * An episode of acute illness or exacerbation of a diagnosis that requires hospitalization or active treatment within the past 3 months. * Current treatment for congestive heart failure, angina, uncontrolled arrythmia, deep vein thrombosis, or other uncontrolled cardiovascular events. * Myocardial infarction, coronary artery bypass grafting, angioplasty, or other cardiac conditions within the past 3 months, * Active cancer for which chemo/radiation therapy is being received. * Psychiatric co-morbidity including major depressive disorder, schizophrenia, psychosis, or other psychiatric illness. * Recent use of any sedating medications (sedatives, anti-psychotics, hypnotics, anti-depressants) or change in medication within the previous month. * Chronic vertigo or other diagnosed vestibular disorders. * Legal blindness, visual impairments that cannot be corrected with glasses, contact lenses, medicine, or surgery. * Those without WiFi access * Those who do not plan to live in their current homes for the duration of the study

Design outcomes

Primary

MeasureTime frameDescription
Gait variabilityBaseline, Immediate post-intervention, 1 month follow upThis measure is captured by both Mobility Lab (APDM Inc) and the smart phone App. Gait variability is defined as the coefficient of variation to validated stride times.

Secondary

MeasureTime frameDescription
Gait speedBaseline, Immediate post-intervention, 1 month follow upThis measure is captured by Mobility Lab (APDM InC). Gait speed id defined by the time one takes to walk a specified distance.
Dual-task gait performanceBaseline, Immediate post-intervention, 1 month follow upParticipants will be asked to walk under two conditions: 1) walk at a comfortable, self-selected speed and 2) walk while counting backward by 1' or 3's from a random 3-digit number. Dual-task gait characteristics will be captured while the participants concurrently walk and count. We will further calculate the cost one takes to complete the dual-task walking from walking at a comfortable, self-selected speed.
Accuracy (d prime) on the gradual onset continuous performance task (gradCPT)Baseline, Immediate post-intervention, 1 month follow upThe gradCPT is a computer-based cognitive task designed to measure sustained attention. Accuracy (d prime) on the gradCPT can be derived from the gradCPT analysis tool box.

Countries

United States

Contacts

PRINCIPAL_INVESTIGATOROn-Yee Lo, Ph.D.

Hinda and Arthur Marcus Institute for Aging Research, Hebrew SeniorLife

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026